By Fineline Cube 
Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced positive topline results from the Phase III DESTINY-Gastric04 study for Enhertu (trastuzumab deruxtecan). The HER2-targeted antibody drug conjugate (ADC) has demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival (OS) in patients with second-line HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Study Results
The positive results from the DESTINY-Gastric04 study indicate that Enhertu has the potential to significantly improve outcomes for patients with HER2-positive gastric or GEJ adenocarcinoma. The drug has shown consistency with previous findings in terms of safety.
Global Registration
Enhertu is registered in over 65 countries for the treatment of HER2-positive breast cancer, non-small cell lung cancer (NSCLC), gastric or gastroesophageal junction adenocarcinoma (GC / GEJC), and other solid tumors.-Fineline Info & Tech